Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celltrion/Pfizer Agree To Wait For Mid-September Inflectra Launch

Executive Summary

Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the innovator on which the copycat was referenced.


Related Content

2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
New $350m Site To Build Pfizer’s China Biosimilar Capacity
New $350m Site To Build Pfizer’s China Biosimilar Capacity
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Court Probes Rationale Of Biosimilars' 180-Day Notice
Court rules biosimilar 'patent dance' optional, but delays Zarxio
Janssen seeks to block Celltrion's infliximab biosimilar


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts